In Brief This Week: Bio-Rad Laboratories; TGen, Van Andel Research Institute; Infosys, Elan; Dotmatix, Boehringer Ingelheim | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories has completed its offer to exchange up to $300 million aggregate principal amount of its 8 percent Senior Subordinated Notes due 2016 for any and all of its outstanding 8 percent Senior Subordinated Notes due 2016 that were issued in a private placement. All of the notes were tendered before the deadline yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.